Wegovy’s Pill Problem: Hims & Hers Challenge Novo Nordisk, Sparking a Price War
Novo Nordisk, once the undisputed leader in the weight-loss drug market with its blockbuster medications Ozempic and Wegovy, is facing a growing storm of competition. The latest blow came Thursday when telehealth company Hims & Hers announced a compounded version of the Wegovy pill for just $49 a month – significantly undercutting Novo Nordisk’s $149 price tag. This move has sent ripples through the pharmaceutical industry, triggering a stock slump for both Novo Nordisk and its rival, Eli Lilly, and prompting Novo Nordisk to vow legal action.
The Rise of Compounded Drugs and the Threat to Big Pharma
Hims & Hers isn’t the first to challenge the dominance of branded GLP-1 drugs. The company has previously offered compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, in injectable form. Compounded drugs are created by pharmacies mixing ingredients, offering a potentially cheaper alternative to FDA-approved medications. However, they are largely unregulated and haven’t undergone the same rigorous testing as brand-name drugs, raising concerns about patient safety.
Novo Nordisk argues that Hims & Hers’ actions are “illegal mass compounding” and pose a “significant risk to patient safety.” The company is preparing to take legal and regulatory action to protect its intellectual property and the integrity of the drug approval process. The FDA has also signaled its intent to crack down on “illegal copycat drugs,” offering some relief to Novo Nordisk’s stock, which initially plummeted nearly 8 percent before partially recovering.
Novo Nordisk’s Tumultuous Year
The challenge from Hims & Hers comes at a difficult time for Novo Nordisk. The company was briefly Europe’s most valuable company but has since seen its stock collapse by over 50 percent in 2025. This decline is partly due to increased competition from Eli Lilly’s Zepbound, which outperformed Wegovy in a head-to-head trial. Novo Nordisk also faced criticism for the high cost of its medications, eventually slashing prices last summer.
Adding to the pressure, Novo Nordisk recently warned that it expects sales to fall this year – its first annual decline in sales in nearly a decade – whereas Eli Lilly anticipates continued growth. Novo Nordisk’s recent success with the Wegovy pill, launched in January, offered a glimmer of hope, with the company claiming it’s selling 15 times faster than the injectable version. However, this advantage may be short-lived, as Eli Lilly plans to release its own pill later this year.
The Future of Weight Loss Medication: Pills vs. Injections
The shift towards pill-based GLP-1 medications is a significant development in the weight-loss market. Pills are generally cheaper and less intimidating than injections, potentially expanding access to these drugs. However, the rise of compounded versions raises questions about quality control and patient safety. The FDA’s stance on regulating compounded drugs will be crucial in shaping the future of this market.
Did you recognize?
Novo Nordisk estimates that approximately one million Americans were using knockoff versions of semaglutide at one point, prompting the company to appeal to the US government to ban imports of key ingredients used in these copycat drugs.
FAQ
Q: What are compounded drugs?
A: Compounded drugs are customized medications made by pharmacies using their own ingredients, rather than being manufactured by pharmaceutical companies.
Q: Are compounded drugs safe?
A: Compounded drugs are largely unregulated and haven’t undergone the same rigorous testing as FDA-approved medications, raising concerns about patient safety.
Q: What is semaglutide?
A: Semaglutide is the active ingredient in both Ozempic and Wegovy, medications used to treat diabetes and promote weight loss.
Q: What is the difference between a compounded drug and a generic drug?
A: Generic drugs are approved by the FDA and are bioequivalent to their brand-name counterparts. Compounded drugs are not FDA-approved and are customized by a pharmacist.
Q: What is a GLP-1 drug?
A: GLP-1 drugs are a class of medications that mimic a natural hormone in the body, helping to regulate blood sugar and promote weight loss.
Pro Tip: Always consult with a healthcare professional before starting any latest medication, including compounded drugs, to discuss the potential risks and benefits.
Explore more articles on health and medicine to stay informed about the latest developments in pharmaceutical innovation and patient care.